Pharvaris N.V. (NASDAQ:PHVS) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Pharvaris N.V. (NASDAQ:PHVS) have received an average recommendation of “Moderate Buy” from the fourteen research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. The average 12 month price objective among analysts that have updated their coverage on the stock in the last year is $51.0769.

A number of equities research analysts have issued reports on PHVS shares. Wall Street Zen downgraded Pharvaris from a “hold” rating to a “sell” rating in a research report on Saturday, July 18th. Morgan Stanley raised their price target on Pharvaris from $41.00 to $46.00 and gave the stock an “overweight” rating in a research report on Thursday, June 25th. HSBC raised shares of Pharvaris to an “overweight” rating in a research note on Thursday, August 13th. Citigroup reissued a “market outperform” rating on shares of Pharvaris in a research note on Thursday, August 13th. Finally, UBS Group set a $74.00 target price on shares of Pharvaris in a report on Wednesday, May 13th.

Pharvaris Stock Up 1.4%

Shares of NASDAQ:PHVS opened at $35.66 on Friday. Pharvaris has a 52 week low of $20.65 and a 52 week high of $38.13. The stock has a market capitalization of $2.33 billion, a P/E ratio of -11.69 and a beta of -2.33. The firm has a fifty day simple moving average of $34.76 and a two-hundred day simple moving average of $31.00.

Pharvaris (NASDAQ:PHVS) last announced its earnings results on Wednesday, August 12th. The company reported ($0.81) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.75) by ($0.06). On average, analysts expect that Pharvaris will post -3.15 earnings per share for the current year.

Insider Buying and Selling

In other Pharvaris news, CEO Berndt Modig sold 2,292 shares of the business’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $34.77, for a total transaction of $79,692.84. Following the completion of the transaction, the chief executive officer owned 130,625 shares in the company, valued at $4,541,831.25. The trade was a 1.72% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Johannes Gerardus Chri Schikan sold 30,712 shares of the company’s stock in a transaction that occurred on Tuesday, June 30th. The shares were sold at an average price of $35.49, for a total value of $1,089,968.88. Following the transaction, the director directly owned 315,167 shares in the company, valued at approximately $11,185,276.83. This represents a 8.88% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 118,655 shares of company stock valued at $4,188,002 in the last ninety days. 11.84% of the stock is owned by company insiders.

Institutional Investors Weigh In On Pharvaris

A number of institutional investors and hedge funds have recently modified their holdings of the business. venBio Partners LLC purchased a new position in Pharvaris during the 2nd quarter valued at $160,569,809. Wellington Management Group LLP purchased a new stake in Pharvaris in the third quarter worth $43,282,000. 5AM Venture Management LLC purchased a new stake in Pharvaris in the second quarter worth $27,581,008. California State Teachers Retirement System lifted its position in shares of Pharvaris by 3,210.1% during the second quarter. California State Teachers Retirement System now owns 799,490 shares of the company’s stock worth $27,646,000 after purchasing an additional 775,337 shares during the last quarter. Finally, Paradigm Biocapital Advisors LP lifted its position in shares of Pharvaris by 72.7% during the third quarter. Paradigm Biocapital Advisors LP now owns 1,835,494 shares of the company’s stock worth $45,796,000 after purchasing an additional 772,583 shares during the last quarter.

Pharvaris Company Profile

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.